A5005280066- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Cardiac Valve Diseases and Treatments
- Cardiomyopathy and Myosin Studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Effects of Exercise
- Cardiovascular Issues in Pregnancy
- Cardiac Structural Anomalies and Repair
- Heart Failure Treatment and Management
- Blood Pressure and Hypertension Studies
- Neuroscience of respiration and sleep
- Pharmacovigilance and Adverse Drug Reactions
- Eosinophilic Disorders and Syndromes
- Thyroid Disorders and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiovascular Health and Risk Factors
- Acute Ischemic Stroke Management
- Neurological Disorders and Treatments
- Quality and Safety in Healthcare
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cerebrovascular and Carotid Artery Diseases
Electrophysiology Research Foundation
2008-2023
Johnson University
2015-2023
Rutgers, The State University of New Jersey
2015-2023
Cotton (United States)
2023
Cardiovascular Research Foundation
2016
Thomas Jefferson University
2016
Boehringer Ingelheim (Germany)
2014-2016
Heidelberg University
2016
Jefferson College
2014
Vanderbilt University Medical Center
2012-2013
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 (D150) with warfarin for stroke prevention in 18 113 patients nonvalvular atrial fibrillation.Cardioversion on randomized treatment was permitted. Precardioversion transesophageal echocardiography encouraged, particularly dabigatran-assigned patients. Data from before, during, 30 days after cardioversion were analyzed. A total 1983 cardioversions performed 1270 patients:...
The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113 patients atrial fibrillation. Those prosthetic heart valves, significant mitral stenosis, valvular disease (VHD) requiring intervention were excluded. Others VHD included.This is a post hoc analysis the trial.There 3950 any VHD: 3101 had regurgitation, 1179 tricuspid 817 aortic 471 193 mild stenosis. At baseline, more failure, coronary disease,...
The Intracardiac Echocardiography Guided Cardioversion Helps Interventional Procedures study evaluated the concordance of intracardiac echocardiography (ICE) with transesophageal (TEE) in patients atrial fibrillation (AF).Patients AF undergoing right heart catheterization underwent left atrium (LA) and interatrial septal (IAS) imaging by TEE ICE. A blinded comparison 2 modalities was performed at a core laboratory. Ninety-five aged 58 ± 12 years completed study. LA profiled all both...
Prevalent atrial fibrillation (AF) is associated with excess cardiovascular (CV) death (D) and hospitalizations (H) in heart failure (HF) preserved ejection fraction (pEF). We evaluated if it had an independent role CVD HFpEF studied its impact on cause-specific mortality HF morbidity.
Background: We undertook a pilot investigation to evaluate the feasibility of novel technique using intracardiac echocardiography (ICE) for intraoperative assessment cardiac resynchronization therapy (CRT). Methods: evaluated ICE imaging left ventricular (LV) function and aortic valvular flow as well safety implementation. was used guide CRT system lead placement, assess impact pacing modes, optimization device programming. Results: Twenty‐three patients underwent imaging. showed global...
Dabigatran is an oral direct thrombin inhibitor (DTI), which has a rapid onset of action and can be given twice daily (b-i-d) without anticoagulation monitoring. To determine the long term safety efficacy dabigatran in patients with atrial fibrillation (AF). AF (n=502) from 53 centers Denmark, Netherlands, Sweden United States were enrolled PETRO study, 12 week comparison between (50, 150, 300 mg b-i-d) warfarin (INR 2–3). 361 rolled over into extension trial (PETRO-Ex). The patient arm...